Loading clinical trials...

Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma | Clinical Trials | Clareo Health

COMPLETEDPhase 2NCT01514344

Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma

Phase II, monocentric, open label study to assess safety and activity of intralesional Rituximab for the treatment of indolent CD20+ lymphoma of conjunctiva.

Lead sponsor: Andres J. M. Ferreri•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment20

Start dateDec 2011

Last updatedAug 4, 2022

Condition

Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma

Locations shown

Dip. Oncoematologia - Fondazione Centro San Raffaele del Monte Tabor

Milan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 4, 2022Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions